Phase I trial of gene therapy for age-related macular degeneration completed

Results from Phase I trial NCT01024998 show that intravitreous gene therapy for age-related macular degeneration is safe and well tolerated. The study, which took place in hospitals across the US, used an rAAV2 vector to express VEGF-neutralising protein sFLT01 in the eye. Modest expression of the gene was achieved in patients receiving the highest dose, without major adverse effects. Patients with pre-existing neutralising antibodies to AAV2 did not show any expression and may not benefit from the treatment. Further studies will be needed to explore higher doses and to more fully understand the role of anti-AAV2 antibodies on expression. 

For the original article, please click here.


Registration for the 25th Anniversary Congress is now open

Congress Rates

Academic member ONSITE €800
Academic non-member ONSITE €1000
Industry member ONSITE €1100
Industry non-member ONSITE €1500
Student member ONSITE €350

*Student registrations include complimentary ESGCT Membership

Becoming an ESGCT Academic or Industry member can save you up to 30% on Non-member congress rates

Please see here for full rates including Workshops